Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1
- PMID: 33123608
- PMCID: PMC7499702
- DOI: 10.1093/ofid/ofaa407
Association of Early Nasopharyngeal Immune Markers With COVID-19 Clinical Outcome: Predictive Value of CCL2/MCP-1
Abstract
Early recognition of severe forms of coronavirus disease 2019 (COVID-19) is essential for an opportune and effective intervention, reducing life-risking complications. An altered inflammatory immune response seems to be associated with COVID-19's pathogenesis and progression to severity. Here we demonstrate the utility of early nasopharyngeal swab samples for detection of the early expression of immune markers and the potential value of CCL2/MCP-1 in predicting disease outcome.
Keywords: COVID-19; chemokines; cytokines; inflammation; prognostic biomarkers.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
References
-
- World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance, 21 March 2020 2020. Available at: https://apps.who.int/iris/handle/10665/331509. Accessed 24 May 2020.
LinkOut - more resources
Full Text Sources
Miscellaneous
